Evaluating how different surgical methods affect quality of life after stomach surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the impact of various digestive tract reconstruction methods on postoperative quality of life in patients undergoing proximal gastrectomy for early-stage gastric cancer and adenocarcinoma of the esophagogastric junction. The study aims to compare the outcomes of total gastrectomy and proximal gastrectomy, focusing on the preservation of gastrointestinal function and overall patient well-being. By analyzing patient data, the research seeks to identify the optimal surgical approach that minimizes long-term quality-of-life issues associated with gastric cancer surgeries.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age from over 18 to under 75 years.
* Preoperative gastroscopic pathological biopsy was performed, and histologically confirmed as carcinoma (papillary adenocarcinoma, tubular adenocarcinoma, mucinous adenocarcinoma, signet ring cell carcinoma, poorly differentiated adenocarcinoma, mixed adenocarcinoma, etc.) or adenoma.
* Diagnosed with upper gastric cancer (T1N0M0, T1N1M0, or T2N0M0) or esophagogastric junction cancer with a diameter ≤4 cm based on the 8th edition of the AJCC staging system, as confirmed by CT, MRI, endoscopic ultrasound, and pathology.
* Undergoing proximal gastrectomy with D2 lymphadenectomy is expected to achieve curative resection, with the remaining gastric volume required to be at least half of the pre-resection volume.
* Performance status of 0 or 1 on ECOG (Eastern Cooperative Oncology Group) scale.
* ASA (American Society of Anesthesiology) class I to III.
* The patient has adequate organ function and is capable of tolerating surgery.
* Written informed consent.

Exclusion Criteria:

* Patients who have received preoperative radiotherapy, chemotherapy, targeted therapy, or immunotherapy.
* Presence of multiple malignant tumors in the stomach.
* History of upper abdominal surgery, except for laparoscopic cholecystectomy.
* History of gastric surgery, except for endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR) for gastric cancer.
* Evidence of distant metastasis diagnosed by thoracoabdominal CT/MRI or PET-CT.
* Pregnant or lactating women.
* History of uncontrolled epilepsy, central nervous system disorders, or psychiatric illness.
* Patients with limb disabilities or motor function impairment.
* History of other malignant diseases within the past five years, except for cured skin cancer and cervical carcinoma in situ.
* Clinically severe (i.e., active) heart disease, such as symptomatic coronary artery disease, New York Heart Association (NYHA) class II or higher congestive heart failure, severe arrhythmia requiring medical intervention, or myocardial infarction within the past six months.
* History of stroke or cerebral hemorrhage within the past six months.
* Severe, uncontrolled recurrent infections or other serious uncontrolled comorbidities.
* Pulmonary function test showing FEV1 \< 50% of the predicted value.
* Patients requiring emergency surgery due to tumor-related complications (e.g., bleeding, perforation, or obstruction).

Where it's running

• First Hospital of Jilin University
  Changchun, Jilin, China Recruiting

Study contacts

• Study coordinator: Quan Wang, Professor
• Email: wquan@jlu.edu.cn
• Phone: +86 15843073207

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BHB810 in advanced gastric and GEJ cancer (early-phase)

  This study tests whether BHB810 can be safely given every two weeks to adults with advanced gastric or GEJ adenocarcinoma and looks at its effect, how the drug behaves in the body, and patient responses.

  Recruiting at 2 sites Phase 1/2 BigHat Biosciences, Inc. · Duarte, California and 2 other locations · NCT07529808

• Combination of T-Dxd and Ramucirumab for HER2 Low Gastric Cancer

  This study is testing a new combination treatment of T-Dxd and Ramucirumab for people with advanced HER2 low gastric cancer who haven't responded to their first treatment.

  Recruiting Phase 1/2 Yonsei University · Seoul, Seoul · NCT05894824

• Evaluating NX-1607 for advanced cancers

  This study is testing a new treatment called NX-1607 to see if it can help people with advanced cancers who have run out of other options.

  Recruiting at 15 sites Phase 1 Nurix Therapeutics, Inc. · Duarte, California and 16 other locations · NCT05107674

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer

  This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.

  Recruiting Phase 2 Samsung Medical Center · Seoul, Gang-Nam · NCT07911280

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.